PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcimmBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Immunology
 
BMC Immunol. 2012; 13: 27.
Published online Jun 1, 2012. doi:  10.1186/1471-2172-13-27
PMCID: PMC3436740
Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice
Abhineet Sheoran,corresponding author1 Kwang-il Jeong,1,2 Jean Mukherjee,1 Anthony Wiffin,1 Pradeep Singh,3 and Saul Tzipori1
1Department of Biomedical Sciences, Cummings School of Veterinary Medicine, Tufts University, 200 Westboro Road Building 20, North Grafton, MA, USA
2Vaccine Research Center, 401 North Middletown Road Pfizer, Pearl River, NY, 10965, USA
3Department of Mathematics, Southeast Missouri State University, 401 North Middletown Road Pfizer, Cape Girardeau, MO, 63701, USA
corresponding authorCorresponding author.
Abhineet Sheoran: Abhineet.sheoran/at/tufts.edu; Kwang-il Jeong: hicari.one/at/gmail.com; Jean Mukherjee: jean.mukherjee/at/tufts.edu; Anthony Wiffin: t_wiff/at/yahoo.com; Pradeep Singh: prad_singh/at/yahoo.com; Saul Tzipori: Saul.tzipori/at/tufts.edu
Received March 8, 2012; Accepted June 1, 2012.
Abstract
Background
Hemolytic uremic syndrome (HUS) leading to acute kidney failure, is a condition linked to the production of primarily Shiga toxin 2 (Stx2) by some E. coli serotypes. We have previously shown that Stx2 A subunit-specific human monoclonal antibody (HuMAb) 5C12, and B subunit-specific HuMAb 5H8 inhibit cultured cell death, and protect mice and piglets from fatal Stx2-intoxication. We have also shown that 5H8 blocks binding of Stx2 to its cell-surface receptor globotriaosyl ceramide (Gb3), whereas Stx2 when complexed with 5C12 binds Gb3 with higher affinity than Stx2. The mechanism by which 5C12 neutralizes Stx2 in vitro involves trapping of Stx2 in the recycling endosomes and releasing it into the extracellular environment. Because of the clinical implications associated with the formation of Stx2/antibody complexes and the potential for trapping and clearance through a severely damaged kidney associated with HUS, we investigated the likely site(s) of Stx2/antibody localization and clearance in intoxicated mice treated with antibody or placebo.
Results
Mice were injected with radiolabeled Stx2 (125I-Stx2) 4 hours after administration of 5C12, 5H8, or phosphate buffered saline (PBS) and the sites of localization of labeled Stx2, were investigated 3, 24 and 48 hours later. The liver recorded statistically much higher concentrations of labeled Stx2 for groups receiving 5C12 and 5H8 antibodies after 3, 24 and 48 hours, as compared with the PBS group. In contrast, highest levels of labeled Stx2 were detected in the kidneys of the PBS group at all 3 sampling times. Mice receiving either of the two HuMAbs were fully protected against the lethal effect of Stx2, as compared with the fatal outcome of the control group.
Conclusions
The results suggest that HuMAbs 5C12 and 5H8 promoted hepatic accumulation and presumably clearance of toxin/antibody complexes, significantly diverting Stx2 localization in the kidneys, the target of Stx2 and the cause of HUS. This is in contrast to the fatal outcome of the control group receiving PBS. The results also confirm earlier observations that both HuMAbs are highly and equally protective against Stx2 intoxication in mice.
Keywords: Shiga toxin, Radiolabel, Antibody, Toxin elimination, Toxin concentration, Pharmacokinetic, Human monoclonal antibody
Articles from BMC Immunology are provided here courtesy of
BioMed Central